Clinical trial

BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study

NCT02683564

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-02-01

PhasePHASE3

Study timeline

Study start (unknown)2016-02-01Date precision: month

Registry last updated2016-02-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rheumatoid Arthritisunresolved

Interventions

BOW015DRUG

RemicadeDRUG · verified · RxNorm: Remicade

Sponsors & collaborators

Epirus Biopharmaceuticals (Switzerland) GmbHlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02683564 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.